Tadalafil Tablet, Film Coated
Product Images NDC 71335-3190

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-3190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure of tadalafil, showing its molecular components and bonds arranged in a specific organic compound configuration.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

This image contains four line graphs showing differences in blood pressure readings over time comparing tadalafil to placebo. The graphs display standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes measured in mmHg. The x-axis represents time in hours (0, 4, 8, 24, 48, 72, 96), and the y-axis shows the difference from placebo in blood pressure values.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

A two-panel line graph showing blood pressure (mmHg) changes over 24 hours post-dose. The top panel plots standing systolic blood pressure changes and the bottom panel supine systolic blood pressure changes. Both panels compare tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over time in hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph depicting systolic blood pressure (BP) changes over 12 hours following administration of tadalafil or placebo in combination with doxazosin. The graph compares four conditions: 20 mg tadalafil at 08:00 and 20:00, placebo at 08:00 and 20:00, each paired with 8 mg doxazosin given once daily at 08:00. The y-axis shows systolic BP changes in mmHg, the x-axis shows time after drug administration in hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic graph depicting plasma tadalafil concentration (μg/L) over time (hours) after different dosing regimens. The curves represent single 20-mg dose, single 5-mg dose, and once-daily 5-mg tadalafil after 5 consecutive days, showing concentration changes with error bars across time points up to 120 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph showing the change from baseline in IPSS Total Score over the duration of treatment in weeks for Tadalafil 5 mg and placebo groups. The graph indicates a greater reduction in IPSS score with Tadalafil compared to placebo over 12 weeks, with significant differences marked at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total scores over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows the change in IPSS total score, with Tadalafil showing greater score reductions than placebo throughout the study period.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph depicting weeks of therapy (0, 4, 12, 26) on the x-axis versus least squares mean change from baseline on the y-axis. It compares the treatment effects of Tadalafil/Finasteride and Placebo/Finasteride, showing a greater decrease in mean change over time for Tadalafil/Finasteride, with statistically significant differences noted at several points.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles), indicating greater improvement with tadalafil across the weeks. Statistical significance is noted at p<0.01.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Label (Lbl713353190)

Label for tadalafil tablets USP, 2.5 mg strength, oral film-coated tablets. The label indicates 90 tablets per package, NDC 71335-3190-1, with Bryant Ranch Prepack as the repackager and Unichem Laboratories Ltd. as the manufacturer. Storage instructions and warnings are also included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.